Name
GLP-1 RAs for Type 2 Diabetes. The Why, When and How (1 CEU*)
Date & Time
Saturday, November 27, 2021, 4:00 PM - 5:00 PM
Elaine Cooke
Description

Diabetes affects one in three Canadians and pharmacists are ideally placed to help patients with this condition. Diabetes is the leading cause of end stage renal disease and cardiovascular disease remains the leading cause of death in individuals with diabetes. The 2020 update to Diabetes Canada pharmacologic treatment of type 2 diabetes recommends utilization of antihyperglycemic agents with demonstrated cardiovascular and renal benefits for patients with a history of CVD and CKD. This presentation discusses the clinical benefits of GLP-RAs, their place in therapy and how pharmacists can help in selection of agents to meet patient concerns as well as counselling on use of GLP-1 RAs and management of side effects.

Location Name
Parq AB
Full Address
JW Marriott Parq Vancouver
39 Smithe St
Vancouver BC V6B 0R3
Canada
Additional information
1 CEU Credit